Sign In
Buy MNPR
$60.56
-0.700 (-1.14%)
At Close: Jun 03, 2026
Monopar Therapeutics Skyrockets 400% on Licensing Deal
08:12am, Friday, 25'th Oct 2024
Monopar Therapeutics NASDAQ: MNPR saw its stock skyrocket over 400% on Thursday after announcing a licensing deal with AstraZeneca. By 2 PM, the stock had traded over 10 million shares, far above its
Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday.
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
07:00am, Thursday, 24'th Oct 2024
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced an agreement with Alexion, AstraZeneca Rare Disease, for a license to ALXN-1840 for Wilson disease. The drug candidate showed promising results in a
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
08:00am, Tuesday, 22'nd Oct 2024
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patient
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
08:00am, Tuesday, 15'th Oct 2024
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
08:00am, Thursday, 12'th Sep 2024
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
04:05pm, Tuesday, 27'th Aug 2024
WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
08:00am, Wednesday, 21'st Aug 2024
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
08:00am, Wednesday, 14'th Aug 2024
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
08:00am, Friday, 09'th Aug 2024
Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
08:00am, Friday, 09'th Aug 2024
WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24
08:00am, Tuesday, 25'th Jun 2024
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today
Monopar and NorthStar Amend & Extend Collaboration
07:30am, Tuesday, 11'th Jun 2024
Highlights: Builds on Companies' respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar's develo
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patient
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
06:15am, Wednesday, 05'th Jun 2024
Penny stocks are risky. That's why we attach a warning to the tail-end of penny stock articles.
